Company Profile

Shire specializes in developing, producing, and marketing pharmaceutical products for the treatment of nervous system dysfunctions (hyperactivity, epilepsy, Alzheimer's disease, etc.), cancer, gastro-intestinal illnesses, and infectious diseases. Net sales break down by source of income as follows: - sales of products (95.3%); - other (4.7%): primarily franchise royalties. Net sales break down geographically as follows: the United States (63.6%), Ireland (0.4%) and other (36%).

Employees

Sector

Pharmaceuticals

More about the company

21/12/18	S&P 500 : Dealmakers brace for slowdown after third-strongest M&A year	RE
21/12/18	Asia M&A clocks second best on record, strength to persist despite trade troubles	RE

21/12/18	S&P 500 : Dealmakers brace for slowdown after third-strongest M&A year	RE
21/12/18	Asia M&A clocks second best on record, strength to persist despite trade troubles	RE
21/12/18	British shares falter as Fed, oil play Scrooge	RE
20/12/18	FTSE : GSK pulls FTSE 100 out of three-day rut, focus on Fed	RE
19/12/18	FTSE : Oil slide and growth worries smother FTSE 100 while mid-caps bounce	RE
18/12/18	FTSE : down sharply as ASOS profit alert sparks wider retail selloff	RE
08/12/18	FTSE : Oil helps FTSE 100 end turbulent week firmer, but Brexit weighs	RE
06/12/18	FTSE : falls as growth angst spreads	RE
06/12/18	Growth and trade nerves grind European shares down to two-week low	RE
06/12/18	Takeda Pharmaceutical : clears key hurdle as investors back $59 billion Shire deal	RE
05/12/18	Takeda Pharmaceutical : investors back $59 billion Shire deal, but wary of debt load	RE
21/11/18	Takeda Pharmaceutical : EU approves Takeda buying Shire, on divestment condition	RE
21/11/18	Takeda Pharmaceutical : Investor advisory firms back Takeda's $62 billion deal for Shire	RE

13/05/20	Takeda Pharmaceutical : Drugmaker Takeda expects 35% rise in net profit on lower buyout costs	AQ
04/02/20	Takeda Pharmaceutical : lifts FY 2019 earnings projections after Shire buyout	AQ
08/01/19	Shire : Form 8.3 - Takeda Pharmaceutical	PU
08/01/19	Shire : Form 8.3 -	PU
08/01/19	Shire : Form 8.5 (EPT/RI) - Replacement of Shire	PU

08/01/19	EN DIRECT DES MARCHES : Nissan, Dassault Aviation, STMicroelectronics, Sika, Samsung, Tessi...
08/01/19	Les affaires reprennent dans la pharmacie
21/12/18	Walt Disney : Le marché du M&A se prépare à une année 2019 moins faste
18/12/18	Shire : plombé par le déclassement de Takeda
06/12/18	Altran Technologies : Les craintes sur les taux et le commerce font plier les actions en Europe

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELI LILLY AND COMPANY	-0.71%	+9.47%	+92.27%	+131.19%	1,098B
JOHNSON & JOHNSON	-0.91%	+1.64%	+49.07%	+49.05%	631B
ABBVIE INC.	+0.43%	+2.16%	+25.39%	+63.67%	438B
ROCHE HOLDING AG	-1.13%	+3.13%	+49.78%	+39.13%	368B
NOVARTIS AG	-0.74%	+1.01%	+31.08%	+38.64%	298B
ASTRAZENECA PLC	-1.22%	+0.89%	+7.32%	+7.38%	251B
AMGEN INC.	-0.67%	+6.28%	+45.39%	+57.90%	226B
NOVO NORDISK A/S	+0.34%	-0.13%	-4.77%	-50.50%	209B
GILEAD SCIENCES, INC.	+2.35%	+1.02%	+13.41%	+70.79%	165B
Average	-0.22%	+1,657.21%	+34.33%	+45.25%	409.37B
Weighted average by Cap.	-0.50%	+1,331.50%	+50.02%	+66.46%

Shire Stock CBOE

Stocks

SHP

JE00B2QKY057

Pharmaceuticals

Latest news : Shire

Analysts' recommendations: Shire

Press Releases: Shire

News in other languages: Shire

Other Pharmaceuticals

Company Profile

End-of-day quote CBOE Other stock markets
- ^GBX	-